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Summary
Background:  Myocyte  injury  might  be  involved  in  the  progression  of  essential  hypertension
(EHT) toward  heart  failure  (HF).  However,  in  the  absence  of  high-sensitivity  (hs)  assay,  cardiac
troponin T  (TnT)  in  EHT  has  not  been  measurable.
Methods  and  results:  We  studied  236  consecutive  ambulatory  patients  (mean  age  =  65.5  years;
110 men)  with  treated  EHT  (mean  systolic  blood  pressure  =  134.3  mmHg,  mean  serum  N-terminal
pro-B-type  natriuretic  peptide  =  86.6  pg/ml)  for  mean  65.6  months.  Patients  with  a  history  of
HF were  excluded.  Single  and  multiple  variable  analyses  were  performed  in  search  of  clinical
correlates  of  elevated  hs-TnT  (≥0.003  ng/ml).
Serum  concentration  of  hs-TnT  was  ≥0.003  ng/ml  (mean  =  0.008  ng/ml)  in  184  patients.  By  sin-
gle variable  analysis,  age,  uric  acid,  log-transformed  N-terminal  pro-B-type  natriuretic  peptide,
brachial-ankle  pulse  wave  velocity,  Cornell  electrocardiographic  (ECG)  voltage,  and  number  of
antihypertensive  medications  were  associated  with  log-transformed  hs-TnT,  while  hemoglobin
and estimated  glomerular  ﬁltration  rate  (eGFR)  were  inversely  correlated  with  log-transformed
hs-TnT. By  multivariate  analysis,  age,  eGFR  and  Cornell  voltage  were  independent  correlates
of log-transformed  hs-TnT,  even  after  adjustment  for  clinical  backgrounds  including  known
prognostic  biomarkers  of  EHT.
Conclusions:  hs-TnT  was  ≥0.003  ng/ml  in  78%  of  patients  presenting  with  treated  EHT  and
independently  correlated  with  age,  renal  function,  and  ECG  voltage  of  hypertrophy.
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ntroductioneveral  studies,  including  ours,  have  found  that  serum
oncentrations  of  cardiac  troponin  T  (TnT)  are  an  inde-
endent  prognostic  biomarker  in  acute  or  chronic  heart
ailure  (HF)  [1—8], and  recently  published  professional
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Table  1  Characteristics  of  the  entire  patient  population
and of  the  study  subgroups.
All  patients
n =  236
Age,  years  65.5  ±  10.7  (38—90)
Women/men  126/110
Height,  cm  157.5  ±  9.4  (130—179)
Body  weight,  kg  62.4  ±  13.3  (35—128)
Body  mass  index,  kg/m2 25.0  ±  4.3  (16.5—45.9)
Duration  of
hypertension,  months
65.6  ±  84.0  (0—456)
Diabetes  mellitus 19  (8)
Hyperlipidemia 61  (26)
Hemoglobin,  g/dl 13.4  ±  1.4  (8.7—16.9)
Estimated  GFR,
ml/min/1.73  m2
69.0  ±  17.1  (16—123)
Uric  acid,  mg/dl  5.5  ±  1.4  (1.5—9.4)
High sensitive  CRP,  mg/dl  0.121  ±  0.149  (0.000—0.990)
N-terminal  pro  BNP,
pg/ml
86.6  ±  86.6  (5—564)
Blood  pressure,  mmHg
Systolic  134.3  ±  14.9  (100—191)
Diastolic  79.6  ±  10.0  (55—130)
Mean  103.3  ±  11.6  (78—153)
Heart  Rate/min  71.7  ±  13.2  (47—122)
Brachial-ankle  pulse
wave  velocity,  cm/s
1,660.8  ±  338.2  (1049—2975)
Electrocardiographic
voltage,  mm
Sokolow—Lyon  26.8  ±  8.0  (12—62)
Cornell,  mm 15.0  ±  5.4  (4—31)
Antihypertensive
regimen
ACE inhibitor  or  ARB  165  (70)
Calcium  antagonist  176  (75)
Beta-adrenergic
blocker
51  (22)
Thiazide  diuretic  55  (23)
Alpha-1  blocker  21  (9)
Number  of
untihypertensive  drugs
2.0  ±  1.0  (0—5)
Values are means ± SD (range), or numbers (%) of observations.
GFR, glomerular ﬁltration rate; CRP, C-reactive protein; BNP, B-
S
A
C
o
y
r
u
t
iHigh-sensitivity  cardiac  troponin  T  in  essential  hypertension
management guidelines  have  assigned  TnT  a  class  IIb  value
in  the  risk  stratiﬁcation  of  patients  suffering  from  HF  [9].
Compared  with  the  TnT  concentrations  measured  in  acute
coronary  syndromes,  which  might  rise  above  1.0  ng/ml  [10],
the  concentrations  measured  in  HF  were  low,  consistently
<0.1  ng/ml  and  averaging  approximately  0.02—0.06  ng/ml
[7,11].  An  increase  in  TnT  has  also  been  found  in  association
with  left  ventricular  remodeling  observed  on  echocardio-
gram  [1,4]. Therefore,  an  elevated  TnT  might  be  a  sign
of  subclinical  myocyte  injury  in  patients  with  HF.  On  the
other  hand,  patients  suffering  from  hypertension  are  at  risk
of  developing  HF,  and  the  progression  of  disease  might  be
due  to  myocyte  injury  [12]. However,  in  the  majority  of
patients  presenting  with  essential  hypertension  (EHT)  and
free  from  HF,  the  TnT  concentrations  are  <0.01  ng/ml  (per-
sonal  observations),  thus  are  undetectable  by  conventional
TnT  assay.
A  high-sensitivity  (hs)  assay  has  recently  become  avail-
able,  which  accurately  measures  low  concentrations  of  TnT
with  a  small  coefﬁcient  of  variation  [7,13]. We  used  this
assay  to  test  our  hypothesis  that  very  small  amounts  of  TnT
are  released  into  the  circulation  of  hypertensive  patients,
in  the  absence  of  HF.
Study population and methods
This  study  included,  between  July  2009  and  June  2010,  236
consecutive  ambulatory  hypertensive  patients  (126  women
and  110  men),  with  a  systolic  pressure  ≥140  mmHg,  diastolic
pressure  ≥90  mmHg,  or  who  were  treated  with  antihy-
pertensive  medications.  Patients  were  excluded  from  this
analysis  if  they  (a)  suffered  from  secondary  hypertension;
(b)  had  a  history  of  HF,  ischemic  heart  disease,  or  atrial
ﬁbrillation;  (c)  were  treated  with  furosemide;  (d)  had  left
or  right  complete  bundle  branch  block  on  surface  electro-
cardiogram;  (e)  were  treated  with  hemodialysis  for  renal
failure;  or  (f)  had  fever  or  a  sign  of  infectious  diseases.
Brachial-ankle  pulse  wave  velocity  (baPWV)  (Nihon  Colin,
Tokyo,  Japan)  and  electrocardiogram  were  recorded,  and
venous  blood  samples  collected  on  the  same  day.  Elec-
trocardiograms  were  interpreted  by  observers  blinded  to
other  clinical  data.  The  severity  of  left  ventricular  hyper-
trophy  was  ascertained  by  the  Sokolow—Lyon  (S  wave  in
V1 +  R  wave  in  V5 and  V6)  and  the  Cornell  (R  wave  in  aVL +  S
wave  in  V3)  electrocardiographic  voltage  calculations  [14].
Hs-TnT  and  N-terminal-pro-B-type  natriuretic  peptide  (NT-
proBNP)  concentrations  were  measured,  using  an  Elecsys
2010  system  (Roche  Diagnostics,  Tokyo,  Japan).  Because  the
equation  for  estimation  of  the  glomerular  ﬁltration  rate
(eGFR)  in  Western  patients  might  not  be  applicable  to  Asian
patients,  we  used  recently  published  equations  for  Japanese
men  (194  ×  serum  creatinine−1.094 ×  age−0.287)  and  women
(194  ×  serum  creatinine−1.094 ×  age−0.287 ×  0.739)  [15]. Dia-
betes  mellitus  (DM)  was  deﬁned  as  a  fasting  serum  glucose
≥126  mg/dl,  non-fasting  serum  glucose  >200  mg/dl,  or  use
of  an  anti-diabetic  medication.  Hypercholesterolemia  was
deﬁned  as  a  total  cholesterol  ≥220  mg/dl,  or  use  of  a
statin.
The  study  procedures  were  in  compliance  with  the  guide-
lines  of  the  Hyogo  Amagasaki  prefecture  Hospital.
w
i
ptype natriuretic peptide; ACE, angiotensin-converting enzyme;
ARB, angiotensin receptor blocker.
tatistical analysis
ll  results  are  presented  as  means  ±  standard  deviation  (SD).
ontinuous  variables  were  compared  by  factorial  analysis
f  variance,  and  dichotomous  variables  by  chi-square  anal-
sis.  Linear  regression  analysis  was  used  to  examine  the
elationship  between  log  transformed  hs-TnT,  as  a contin-
ous  variable,  and  the  baseline  characteristics.  Variables
hat  were  signiﬁcant  in  the  single  variable  analysis  were
ncluded  in  the  multiple  variable  model,  and  a stepwise  for-
ard  multiple  variable  analysis  was  carried  out  to  identify
ndependent  correlations.  A  logistic  regression  analysis  was
erformed  to  examine  the  relationship  between  elevated
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migure  1  Distribution  of  (A)  hs-TnT.  (B)  Log  transformed  hs-
nT. hsTnT,  high-sensitivity  cardiac  troponin  T.
s-TnT  ≥0.003  ng/ml  and  clinical  characteristics.  A  p-value
0.05  was  considered  statistically  signiﬁcant.  All  statisti-
al  analyses  were  performed  using  the  Statview  software,
ersion  5.0  (SAS  Institute,  Cary,  NC,  USA).
esults
erum  hs-TnT  concentrations
able  1  shows  the  characteristics  of  the  236  patients.
s-TnT  was  ≥0.003  ng/ml  in  184  patients,  averaging
.008  ±  0.005  ng/ml  (range  0.003—0.029).  The  distribution
f  hs-TnT  is  shown  in  Fig.  1a,  and  the  log-transformation
s  shown  in  Fig.  1b.  The  hs-TnT  concentrations  were  simi-
ar  in  men  and  women  (both  means  =  0.008  ±  0.005  ng/ml).
he  mean  concentration  of  simultaneously  measured
T-proBNP  was  86.6  pg/ml,  below  the  125-pg/ml  thresh-
ld  value  consistent  with  a  diagnosis  of  chronic  HF
16].
utcome  of  analysis  in  patients  with  serum  hs-TnT
oncentrations ≥0.003  ng/ml
e  examined  the  relationships  between  log-transformed
s-TnT  and  the  clinical  variables  listed  in  Table  1  in  the
i
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84 patients  whose  hs-TnT  was  ≥0.003  ng/ml.  Age,  uric
cid,  log(NT-proBNP),  baPWV,  Cornell  voltage,  and  num-
er  of  antihypertensive  drugs  were  correlated  with  log
s-TnT,  while  hemoglobin  and  eGFR  were  inversely  cor-
elated  with  log  hs-TnT  (Table  2).  By  multiple  variable
egression  analysis,  age,  eGFR,  and  Cornell  voltage  (as
oth  continuous  variable  and  categorical  variable)  were
orrelated  with  log  hs-TnT  after  adjustment  for  clinical
ackgrounds  including  known  clinical  prognostic  biomarkers
f  EHT  (high  sensitive  C  reactive  protein,  hemoglobin,  uric
cid,  log  transformed  NT-proBNP,  and  pulse  wave  velocity)
Table  3).
Logistic  regression  analysis  was  also  performed  to  exam-
ne  the  correlation  between  hs-TnT  ≥0.003  ng/ml  and  eight
ositive  parameters  listed  in  Table  2  and  Sokolow—Lyon
oltage.  Univariate  logistic  regression  analysis  showed  that
ge,  eGFR,  uric  acid,  log  transformed  NT-proBNP,  and
okolow—Lyon  voltage  were  signiﬁcantly  correlated  with  hs-
nT  ≥0.003  ng/ml.  Multivariate  analysis  showed  that  age,
GFR,  and  Sokolo-Lyon  voltage  (as  both  continuous  variable
nd  categorical  variable)  were  independently  correlated
ith  hs-TnT  ≥0.003  ng/ml  (Table  4).  When  adjusted  by  uric
cid  and  log  NT-proBNP,  Sokolow—Lyon  voltage  remained  sig-
iﬁcant  (data  not  shown).
iscussion
hile  it  is  widely  accepted  that  the  TnT  tests  aimed  at
etecting  a  myocardial  infarction  require  a  <10%  coefﬁcient
f  variation  at  the  99th  percentile  of  a  normal  reference
opulation  [10], conventional  TnT  assays  do  not  satisfy
his  criterion,  and  the  measurements  of  low  concentra-
ions  are  not  accurate.  hs-TnT,  used  in  this  study,  fulﬁlls
he  criterion  of  ‘‘high-sensitivity’’  and  is  accurate  at  low
oncentrations  [7,13]. The  intra-assay  coefﬁcient  varia-
ion  of  hs-TnT  has  been  reported  to  be  5%  at  0.01  ng/ml
7].  The  limit  of  blank  is  0.003  ng/ml  and  the  analyti-
al  range  of  the  assay  is  0.003—10  ng/ml  [13]. Therefore,
e  investigated  patients  with  hs-TnT  ≥0.003  ng/ml  in  this
tudy.
It  is  noteworthy  that,  in  our  population,  hs-TnT  did  not
orrelate  with  blood  pressure,  and  that  78%  of  the  patients
ad  hs-TnT  ≥0.003  ng/ml  despite  moderately  controlled
ystolic  blood  pressure  (mean  =  134.3  mmHg).  Furthermore,
he  mean  serum  concentration  of  hs-TnT  in  EHT  was
.008  ng/ml  and  most  patients  showed  hs-TnT  less  than
.02  ng/ml  as  seen  in  Fig.  1A,  in  contrast  to  the  approx-
mately  0.02—0.06  ng/ml  measured  in  patients  suffering
rom  chronic  HF  [7,11]. Therefore,  hs-TnT  concentrations
bserved  in  EHT  are  very  subtle  compared  with  that
bserved  in  HF.  As  the  conventional  TnT  assay  does  not  mea-
ure  concentrations  <0.01  ng/ml,  this  is,  to  the  best  of  our
nowledge,  the  ﬁrst  report  of  hs-TnT  measurements  in  EHT
n  absence  of  overt  HF.
The  troponin  complex  consists  of  proteinic  subunits  C,
,  and  T  mostly  bound  to  the  actin  ﬁlaments  of  striated
uscle,  while  only  6—8%  of  all  TnT  is  present  unboundn  the  cytosol.  Therefore,  the  release  of  TnT  into  the
irculation  is  a  manifestation  of  reversible  or  irreversible
yocyte  injury  [17,18].  In  patients  presenting  with  HF,  we
nd  others  have  found  correlations  between  elevated  serum
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Table  2  Correlates  of  high-sensitivity  cardiac  troponin  T  ≥0.003  ng/ml  by  single  variable  analysis.
Single  variable
Correlation  coefﬁcient p
Age,  years 0.452  <0.0001
Gender (male  =  1) 0.9654
Height,  cm 0.0900
Body  weight,  kg  0.2714
Body mass  index,  kg/m2 0.9930
Duration of  hypertension  treatment,  months  0.2615
Diabetes mellitus  (yes  =  1)  0.1409
Hyperlipidemia  (yes  =  1)  0.7805
Hemoglobin,  g/dl  −0.171  0.0204
Estimated glomerular  ﬁltration  rate,  ml/min/1.73  m2 −0.397  <0.0001
Uric acid  (mg/dl)  0.174  0.0180
High sensitive  C-reactive  protein  (mg/dl)  0.3437
Log N-terminal-pro-B-type  natriuretic  peptide,  pg/ml  0.281  0.0001
Blood pressure,  mmHg
Systolic  0.5142
Diastolic 0.1977
Mean 0.8647
Heart rate,  beat/min  0.2554
Brachial-ankle  pulse  wave  velocity,  cm/sec  0.316  <0.0001
Electrocardiographic  voltage,  mm
Sokolow—Lyon  0.8286
Cornell 0.196  0.0076
c
t
cNumber of  antihypertensive  drugs  
TnT  and  elevated  serum  BNP,  renin  and  norepinephrine
suggesting  that  myocardial  load,  activation  of  the  renin-
angiotensin-aldosterone  and  sympathetic  nervous  systems
are  causes  of  myocyte  injury  in  patients  with  chronic  HF
[7,11].  It  has  been  hypothesized  that  apoptosis  of  car-
diomyocytes  plays  an  important  role  in  the  transition  from
i
a
a
Table  3  Correlates  of  high-sensitivity  cardiac  troponin  T  ≥0.003  
Not
CC  
Age  0.3
eGFR −0.2
Cornell voltage  (as  continuous  variable)  0.1
Not
CC  
Age  0.3
eGFR −0.2
Cornell voltage  (as  categorical  variable,  ≥median)  0.1
By multiple variable regression analysis, age, eGFR and Cornell volta
correlated with log high-sensitivity cardiac troponin T after adjustme
biomarkers of essential hypertension (high-sensitive C-reactive protein
natriuretic peptide and pulse wave velocity).
a Adjusted for gender and known prognostic biomarkers (high-sensi
N-terminal pro B type natriuretic peptide, pulse wave velocity).
CC, correlation coefﬁcient; eGFR, estimated glomerular ﬁltration rate0.148  0.0451
ompensatory  hypertrophy  to  pump  failure  in  experimen-
al  and  human  hypertension.  Putative,  though  unconﬁrmed,
auses  of  cardiomyocyte  apoptosis  in  overloaded  hearts
nclude  mechanical  and  oxidative  stress,  neuro-humoral
ctivation,  hypoxia,  and  cytokines  in  EHT  [12]. The  avail-
bility  of  the  new  assay,  will  enable  studies  in  search  of
ng/ml  by  multiple  variable  analysis.
 adjusted  Adjusteda
p  CC  p
41  <0.0001  0.294  0.0005
42  0.0007  −0.190  0.0139
68  0.0084  0.165  0.0108
 adjusted  Adjusteda
p  CC  p
51  <0.0001  0.311  0.0002
40  0.0008  −0.191  0.0136
61  0.0101  0.147  0.0252
ge (as both continuous variable and categorical variable) were
nt for clinical backgrounds including known clinical prognostic
, hemoglobin, uric acid, log transformed N-terminal pro B type
tive C-reactive protein, hemoglobin, uric acid, log transformed
.
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Table  4  Correlates  of  high-sensitivity  cardiac  troponin  T  ≥0.003  ng/ml  by  logistic  regression  analysis.
Analysis
Single  variable
Odds  ratio  (95%  CI)
Multiple  variable  Odds  ratio
(95%  CI)
Age 1.056  (1.025—1.088)
p =  0.0003
1.044  (1.011—1.079)
p =  0.0095
1.042  (1.009—1.077)
p  =  0.0129
Estimated glomerular  ﬁltration  rate 0.967  (0.948—0.986)
p =  0.0008
0.972  (0.951—0.994)
p =  0.0132
0.975  (0.954—0.997)
p  =  0.0254
Sokolow—Lyon  voltage  (as  continuous
variable)
1.049  (1.005—1.095)
p =  0.0286
1.068  (1.019—1.119)
p =  0.0062
—
Sokolow—Lyon  valtage  (as  categorical
variable,  ≥35  mm)
3.020  (1.024—8.911)
p =  0.0452
—  3.319  (1.091—10.101)
p  =  0.0346
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categorical variable) were independently correlated with high-sen
orrelations  between  hs-TnT  and  other  laboratory  and  clin-
cal  observations  in  EHT.
The  mechanisms  of  TnT  elevation  in  patients  with  renal
ailure  are  also  unresolved.  Several  investigators  hypothe-
ized  initially  that  uremia-induced  skeletal  myopathy  might
e  the  source  for  pseudo  positive  TnT.  However,  with  the
ecent  development  of  a  speciﬁc  assay,  there  seem  to  be
nsufﬁcient  data  to  support  a  skeletal  muscle  source  as
n  explanation  for  the  increase  in  TnT  concentrations  in
atients  with  renal  failure  and  the  elevation  of  TnT  is  a  prog-
ostic  factor  in  this  clinical  setting  [19]. Furthermore,  one
tudy  found  that  TnT  is  fragmented  into  molecules  small
nough  to  be  excreted  by  the  kidney  [20]. Therefore,  the
enal  clearance  might  inﬂuence  the  serum  concentrations
f  TnT.
Our  study  is  limited  by  its  small  sample  size,  and  by  the
ollection  of  data  from  a  single  institution.  Since  only  8
atients  had  never  been  treated  for  EHT,  the  outcomes  of  a
imilar  study  in  untreated  patients  might  be  different.  The
ifference  between  the  Sokolow—Lyon  and  Cornell  voltage
riteria  remains  unexplained.  Moreover,  echocardiographic
ndings  are  superior  to  ECG  to  detect  left  ventricular
ypertrophy.  However,  our  results  showed  the  signiﬁcant
orrelation  between  ECG  voltage  of  hypertrophy  and  hs-
nT,  and  may  support  the  previous  study  that  showed  the
igniﬁcant  correlation  between  left  ventricular  hypertrophy
nd  TnT  in  the  general  population  [21]. This  will  need  to  be
xamined  in  a  larger  study  using  other  means  of  detection
f  left  ventricular  hypertrophy,  used  in  other  large  clinical
rials  [14].
In  conclusion,  in  this  population  of  patients  treated  for
HT,  hs-TnT  was  ≥0.003  ng/ml  in  78%  of  patients.  Hs-TnT
as  correlated  with  age,  eGFR,  and  ECG  voltage  of  hyper-
rophy.  Further  studies  might  be  needed  to  determine  the
ormal  range  of  hs-TnT  and  normal  range  should  be  deter-
ined  in  young  people  without  overt  renal  disease  and  heart
isease  including  hypertension.cknowledgment
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